Talley and a the vice president from Cephalon will inform about the topic above. Will we have the first numbers from sales here? :-)
"On Wednesday, September 30th, key stakeholders in the debate over access will convene in Washington, DC to share their perspectives in an interactive forum. The goal of this first-of-its-kind event is to provide a better understanding of the many viewpoints surrounding access to investigational drugs."
I know we have too many catalysts that will pop EPCT pps in the next three months but I never thought of this one. It is great news for the U.S Acute Myeloid Leukemia patients that they will have access to Ceplene right away BEFORE the FDA approval.
Great job as usual, Larshan ! This will start us off for the next 3 months.
“Confirmed panelists to date include:
- Rachel E. Behrman, MD, MPH, Associate Commissioner for Clinical Programs & Director of Critical Path Initiative, Food and Drug Administration - Gerard Kennealey, MD, Vice President, Business Development, Cephalon, Formerly Vice President, Oncology Clinical Research at AstraZeneca - Jack V. Talley, President & CEO, EpiCept - Patricia Furlong, President & CEO, Parent Project Muscular Dystrophy - Emil Kakkis, MD, PhD, President, Kakkis EveryLife Foundation - Peter L. Saltonstall, President & CEO, National Organization for Rare Disorders (NORD)”